Dose-response relationships for edrophonium and neostigmine antagonism of atracurium and cisatracurium- induced neuromuscular block

Canadian Journal of Anesthesia

Volumn 47, Issue 11, 2000, Pages 1074-1081

  Naguib, Mohamed ^a   Riad, Waleed ^b  

^a UNIVERSITY OF IOWA   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; CARBON DIOXIDE; CISATRACURIUM; EDROPHONIUM; FENTANYL; ISOFLURANE; LORAZEPAM; NEOSTIGMINE; NITROUS OXIDE; OXYGEN; RINGER LACTATE SOLUTION; THIOPENTAL;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE TWITCH; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; RANDOMIZATION; TRANSDUCER;

ADOLESCENT; ADULT; ATRACURIUM; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDROPHONIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION;

EID: 0034581876     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03027958     Document Type: Article

References (24)

1. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia
2. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination
3. Measurement of acceleration: A new method of monitoring neuromuscular function
4. The Accelograph®: A new neuromuscular transmission monitor
5. Biodegradable neuromuscular blocking agents. Part 6- Stereochemical studies on atracurium and related polyalkylene di-esters
6. The pharmacokinetics of atracurium isomers in vitro and in humans
7. Comparative pharmacology of cisatracurium (51W89), atracurium and five isomers in cats
8. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose)
9. The pharmaco-kinetics and pharmacodynamics of atracurium in patients with and without renal failure
10. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia
11. Clinical pharmacology of atracurium besylate (BW 33A): A new nondepolarizing muscle relaxant
12. In vitro degradation of atracurium in human plasma
13. Elimination of atracurium in humans: Contributions of Hofmann elimination and ester hydrolysis versus organ-based elimination
14. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma
15. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients
16. Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade
17. Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade
18. Dose-response relationships for edrophonium and neostigmine antagonism of mivacurium-induced neuromuscular block
19. Dose-response relationships for edrophonium and neostigmine antagonism of pipecuronium-induced neuromuscular block
20. Dose-response relationships for edrophonium and neostigmine as antagonists of moderate and profound atracurium blockade
21. Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine
22. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties